Lithium and the risk of severe COVID-19 infection: A retrospective population-based register study.
JSON
Nilsson NH, Bendix M, Öhlund L, Gibbs A, Widerström M, Werneke U, Maripuu M
J Psychosom Res 190 (-) 112053
[2025-03-00; online 2025-02-13]
Previous research has suggested antiviral properties for lithium, including potential effectiveness against COVID-19 in vitro. This study aimed to investigate the impact of lithium and other psychotropic drugs on the risks of mortality, hospitalization, and ICU admission due to COVID-19 among individuals with bipolar disorder. The primary objective was to assess whether lithium was beneficial in COVID-19-infection in a real-world population. Retrospective register study using data from multiple Swedish patient registers, including 39,063 individuals in Sweden with bipolar disorder and prescribed mood stabilizers. Outcomes included COVID-19-associated death, hospitalization, and ICU admission between 11 March 2020 and 10 March 2021. Multivariate logistic regression adjusted for age, sex, and somatic comorbidities was conducted. Lithium were prescribed to 44.2 % of patients, either as mono- or combination therapy; other mood stabilizers were prescribed to 55.8 %. There were no significant associations between lithium and COVID-19-associated death, hospitalization, or ICU admission. Atypical antipsychotics were associated with increased odds ratios for COVID-19-associated death (OR 1.58 [95 % CI 1.01-2.47]), hospitalization (OR 1.80 [95 % CI 1.49-2.18]), and ICU admission (OR 2.25 [95 % CI 1.33-3.80]). Benzodiazepines were associated with a significant increase in COVID-19-associated death (OR 1.54 [95 % CI 1.01-2.35]) and hospitalization OR 1.26 [95 % CI 1.03-1.53]). In an ad hoc analysis, lithium monotherapy was, however, associated with reduced hospitalizations and ICU admissions. Our findings weaken the hypothesis that lithium reduces the risk of severe events associated with COVID-19 infection in bipolar disorder.
PubMed 39965301
DOI 10.1016/j.jpsychores.2025.112053
Crossref 10.1016/j.jpsychores.2025.112053
pii: S0022-3999(25)00017-0